Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRISA for Consolidation in Post-Transplant Hodgkin Lymphoma Randomized Phase 3 Clinical Trial with ADCETRIS Demonstrates Statistically Significant Improvement in Progression-Free Survival Abstract Submitted to ASH for Presentation at the 2014 Annual Meeting; Regulatory Submissions Anticipated in 2015 Seattle Genetics to Host Conference Call and Webcast Today at 8:30 a.m. ET BOTHELL, Wash.
http://ift.tt/YBPzWI
http://ift.tt/YBPzWI
No comments:
Post a Comment